Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies

St. Justine's Hospital

Status and phase

Completed

Phase 2

Phase 1

Conditions

Cancer

Treatments

Drug: Decitabine and Genistein

Study type

Interventional

Funder types

Other

Identifiers

NCT02499861

DEC-GEN001

Details and patient eligibility

About

This Phase I/IIa study will test the combination of the epigenetic drug decitabine with the isoflavone genistein in children with leukemias and solid tumors. For the phase I study, the maximum tolerated dose will be evaluated in pediatric patients with relapsed or refractory leukemia and solid tumors. For the phase II study, only patients with relapsed or refractory leukemias will be included. To further evaluate the treatment efficacy and gain further insight into action of these drugs, the DNA methylation levels before and after treatment for all participants, pharmacokinetics parameters such as through level for decitabine and through and peak level for genistein will be measured. Pharmacogenomics testing for decitabine will be performed prior to cycle 1 of treatment.

Decitabine will be administered over a 24 hours infusion on day 1 of cycle (28 days) and genistein will be taken orally twice daily from day 2 to 21, followed by a 7 days rest period.

Enrollment

6 patients

Sex

All

Ages

2 to 20 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥ 2 years of age and < 21 years of age at time of study enrollment
Able to swallow genistein or take it with a puree.
Patients must have a diagnosis of recurrent or refractory solid tumors, including Central Nervous System tumors, lymphoma or leukemia for which standard curative measures do not exist or are no longer effective
For solid tumors, patients must have either measurable or evaluable disease. For leukemia, patients must have > 5% blasts in the bone marrow.
Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy.
Performance level: Karnofsky ≥50% for patients ≥ 16 years of age or Lansky ≥ 50% for patients < 16 years of age
Life expectancy at least one month
Patients must have adequate bone-marrow function
Patients must have normal organ as defined below: (total bilirubin ≤ 24microM/L), Amylase/pancreatic amylase≤1.5 × institutional upper limit of normal, Aspartate Aminotransferase (AST) /Alanine Aminotransferase (ALT) ≤2.5 × institutional upper limit of normal, creatinine clearance ≥60 mL/min/1.73 m2.

OR creatinine according to age/gender

Nervous system disorders (CTCAE v4) resulting from prior therapy must be ≤ Grade 2
Participants of child-bearing potential and men must agree to use adequate contraception for the duration of study treatment, and 4 months after completion of decitabine and genistein administration.
All patients and/or their parents or legally authorized representatives must sign a written informed consent

Exclusion criteria

Prior decitabine or genistein therapy.
Patients who are receiving any other investigational agents.
Nasogastric or gastrostomy (or equivalent) administration of genistein is not allowed.
Patients with known exclusive non-measurable leptomeningeal disease at enrolment should be excluded from this clinical trial.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine and genistein.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (receiving antibiotics), symptomatic heart or lung disease, or psychiatric illness/social situations that would limit compliance with study requirements.
Pregnant or breast-feeding women are excluded from this study. All girls of child bearing potential must have a negative pregnant test prior to enrolment.
Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.